GALT (Galectin Therapeutics) Earnings per share growth rate in current year

Official company branding of galectintherapeutics.com (GALT)

Galectin Therapeutics (GALT) is protected by patents for combating cirrhosis and strict FDA oversight, while the firm's environmental footprint remains minimal. Year-over-year EPS dynamics on the GURU.Markets chart demonstrate business resilience, where the current parameter equals 37.50. The company is highly regarded within the scientific community for its deep expertise in fibrosis therapy and its pursuit of solutions for severe pathologies.

GALT (Galectin Therapeutics, Inc.) Earnings growth in current year history from 07/04/2022 to 11/15/2026

Analytical breakdowns and data insights for company Galectin Therapeutics, Inc. (GALT)

- share price and consensus valuation forecast:
Price Chart Galectin Therapeutics, Inc.|GALT - Analyst Consensus Forecast
- business market valuation indicators:
Market Value Galectin Therapeutics Inc.|GALT - Total Company Value
- balance sheet equity data:
Accounting Value of a Share Galectin Therapeutics|GALT - Book Capitalization|Market Value to Equity Ratio galectintherapeutics.com|GALT - Company Total Assets
- debt and liquidity details:
Total Debt to Capital Galectin Therapeutics|GALT - Long-Term Debt to Equity|Short-Term Debt to Equity Galectin Therapeutics, Inc.|GALT - Company Aggregate Debts|Debts to Book Value Galectin Therapeutics|GALT - Company Long-Term Debts|Company Current Liabilities Galectin Therapeutics|Intermediate Liquidity Ratio galectintherapeutics.com
- net income and valuation multiples indicators:
GALT - Net Profit|Company Profit Forecast Galectin Therapeutics|GALT - Price to Earnings Ratio|Price to Future Earnings Ratio Galectin Therapeutics|GALT - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Galectin Therapeutics, Inc.|GALT - Operating profit before deduction of amortization|Earnings per share for the last four quarters Galectin Therapeutics|GALT - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months galectintherapeutics.com|GALT - Earnings growth in current year|Expected net earnings per share growth next year Galectin Therapeutics
- sales volume and revenue information:
GALT - Company Revenue|Company Future Revenue Galectin Therapeutics, Inc.|GALT - P/S Multiple|Forward P/S Multiple Galectin Therapeutics Inc.|GALT - Sales Growth YoY (Last Twelve Months)
Fundamental valuation:GALT Galectin Therapeutics
Manufactured product of Galectin Therapeutics Inc.

For Galectin Therapeutics (GALT), the annual percentage growth of net income per share serves as an indicator of financial stability amid costly clinical trials for cirrhosis drugs. This metric captures EPS dynamics relative to the previous year, allowing for an assessment of how effectively the company manages capital and minimizes cash flow gaps while awaiting regulatory approvals and scientific validation of inhibitor efficacy.

Direct competitors

ARWR (Arrowhead Pharmaceuticals Inc) - Earnings per share growth in current year|MIRM (Mirum Pharmaceuticals, Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Dynavax Technologies Corporation DVAX|Earnings per share growth in current year Arbutus Biopharma Corporation (ABUS)|Expected net earnings per share growth this year Inventiva SA|Earnings growth in current year GYRE (Gyre Therapeutics Inc)|Earnings growth in current year Assembly Corp ASMB|Genfit Corp - Earnings growth in current year|DRRX - Earnings growth in current year|ALGS: Earnings growth in current year|Earnings per share growth rate in current year BioVie Inc. (BIVI)|Earnings per share growth in current year galmedpharma.com|NDRA: Earnings per share increase in current year|Earnings per share growth in current year Hepion Pharmaceuticals (HEPA)